This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Analysts' Actions: CHK, JNJ, BIIB, CNO, UNH


Chase (CCF) downgraded to hold at TheStreet Ratings.

Chesapeake Energy (CHK - Get Report) downgraded at Bernstein from Outperform to Market Perform, Bernstein Research said. $21 price target. Company lacks near-term catalysts.

Majesco Entertainment (COOL) downgraded to hold at TheStreet Ratings.

E*Trade (ETFC) upgraded at BGB from Sell to Hold, BGB Securities said. Valuation call, based on a $7.50 price target.

Fortinet (FTNT) upgraded at UBS to Buy from Neutral, UBS said. $28 price target. Upside to street estimates on increasing market share.

Genon Energy (GEN) upgraded at UBS to Neutral from Sell, UBS said. $1.50 price target. Shares fairly valued.

Hill-Rom (HRC) upgraded at BofA/Merrill from Underperform to Neutral, Bank of America/Merrill Lynch said. Valuation call, based on a $34 price target.

Johnson & Johnson (JNJ - Get Report) upgraded at JP Morgan from Neutral to Overweight, JP Morgan said. $74 price target.

McDonald's (MCD) downgraded at Goldman from Buy to Neutral, Goldman Sachs said. $92 price target. Company faces multiple growth headwinds.

Navistar (NAV) upgraded at JP Morgan from Underweight to Neutral, JP Morgan said. Risk/reward is more balanced at current levels.

Petrologistics (PDH) rated new Buy at UBS. $16.50 price target. Propylene price dip and stock weakness gives a good buying opportunity.

PetSmart (PETM) rated new Overweight at Morgan Stanley. $75 price target. Company can deliver stable growth and gain market share.

Power Integrations (POWI) downgraded at Sterne Agee from Buy to Neutral, Sterne Agee said. Company will likely face weaker customer demand. $43 price target.

UnitedHealth (UNH - Get Report) rated new Overweight at JP Morgan. $72 price target. Company remains a core holding, despite industry regulatory risks.

Woodward (WWD) rated new Buy at Keybanc. $45 price target. Company is leveraged to late-cycle secular growth.


Biogen Idec (BIIB - Get Report) target raised at Oppenheimer to $145. Analyst day highlights pipeline strength. Outperform rating.

CNO Financial (CNO - Get Report) added to Conviction Buy List at Goldman. Company can grow faster than its life insurance peers. Buy rating and $9 price target.

Forest Laboratories (FRX) estimates cut at Morgan Stanley through 2014, Morgan Stanley said. Company lowered its guidance. $35 price target.

Great Plains Energy (GXP) added to Top Picks Live! at Citigroup. $23 price target. Valuation gap should narrow as rates come closer to fruition and regulatory concerns diminish.

Hershey (HSY) added to Conviction Buy List at Goldman. Company can deliver above-average sales and earnings growth. $76 price target.

JPMorgan Chase (JPM) target lowered at Oppenheimer to $56. Contraction of market multiple. Outperform rating.

Mastercard (MA) numbers lowered at Jefferies. Shares of MA now seen reaching $507, Jefferies said. Estimates also lowered on FX and macro risks. Buy rating.

Altria (MO) target raised at Morgan Stanley to $30, according to Morgan Stanley. There's room for industry price increases in the U.S.

Scotts Miracle-Gro (SMG) numbers cut at BofA/Merrill. Shares of SMG now seen reaching $39, according to Bank of America/Merrill Lynch. Estimates also reduced, given the company's new guidance. Underperform rating.

AT&T (T) target raised at Jefferies to $36, Jefferies said. Divestiture of Advertising Solutions should help value gap close. Hold rating.

>To submit a news tip, email:


Follow TheStreet on Twitter and become a fan on Facebook.
This article was written by a staff member of TheStreet.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BIIB $293.21 0.00%
CNO $20.26 0.00%
CHK $5.26 0.00%
JNJ $102.37 0.00%
UNH $114.34 0.00%


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs